Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment
Authors:
- Sebastiaan F. TeunissenSTSebastiaan F. Teunissen
- Filip Y.F.L. de VosFVFilip Y.F.L. de Vos
- Walter J. LoosWLWalter J. Loos
- Ron H.N. van SchaikRSRon H.N. van Schaik
- Felix E. de JonghFJFelix E. de Jongh
- Aad I. de VosAVAad I. de Vos
- Robbert J. van AlphenRARobbert J. van Alphen
- Bronno van der HoltBHBronno van der Holt
- Jaap VerweijJVJaap Verweij
- Caroline SeynaeveCSCaroline Seynaeve
- Jos H. BeijnenJBJos H. Beijnen
- 20 August 2011
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (24) , 3240-3246
Abstract
Purpose Tamoxifen, a widely used agent for the prevention and treatment of breast cancer, is mainly metabolized by CYP2D6 and CYP3A to form its most abundant active metabolite, endoxifen. Interpatient variability in toxicity and efficacy of tamoxifen is substantial. Contradictory results on the value of CYP2D6 genotyping to reduce the variable efficacy have been reported. In this pharmacokinetic study, we investigated the value of dextromethorphan, a known probe drug for both CYP2D6 and CYP3A enzymatic activity, as a potential phenotyping probe for tamoxifen pharmacokinetics. Methods In this prospective study, 40 women using tamoxifen for invasive breast cancer received a single dose of dextromethorphan 2 hours after tamoxifen intake. Dextromethorphan, tamoxifen, and their respective metabolites were quantified. Exposure parameters of all compounds were estimated, log transformed, and subsequently correlated. Results A strong and highly significant correlation (r = −0.72; P < .001) was found between the exposures of dextromethorphan (0 to 6 hours) and endoxifen (0 to 24 hours). Also, the area under the plasma concentration–time curve of dextromethorphan (0 to 6 hours) and daily trough endoxifen concentration was strongly correlated (r = −0.70; P < .001). In a single patient using the potent CYP2D6 inhibitor paroxetine, the low endoxifen concentration was accurately predicted by dextromethorphan exposure. Conclusion Dextromethorphan exposure after a single administration adequately predicted endoxifen exposure in individual patients with breast cancer taking tamoxifen. This test could contribute to the personalization and optimization of tamoxifen treatment, but it needs additional validation and simplification before being applicable in future dosing strategies.Keywords
This publication has 43 references indexed in Scilit:
- The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerBritish Journal of Cancer, 2010
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6Journal of Clinical Oncology, 2010
- Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer PatientsThe Journal of Clinical Pharmacology, 2010
- Germline Pharmacogenetics of Tamoxifen Response: Have We Learned Enough?Journal of Clinical Oncology, 2007
- Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 GenotypesJournal of Clinical Oncology, 2007
- Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug ResponseClinical Pharmacology & Therapeutics, 2007
- Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen TrialJournal of Clinical Oncology, 2006
- Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot FlashesJournal of Clinical Oncology, 2005
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI: Journal of the National Cancer Institute, 2003